Masimo (MASI) stock is drawing fresh attention after the company received FDA 510(k) clearance for its pediatric Patient State Index sedation score, a first-of-its-kind tool tailored to children’s brain physiology. See our latest analysis for Masimo. Masimo's latest share price of $179.95 comes after a period where the stock has recorded a 41.25% year to date share price return and a 7.09% total shareholder return over the past year. This suggests momentum has been building as product related...

Earlier in 2026, Masimo voluntarily initiated global Class II recalls of certain Radius VSM ECG assemblies and blood pressure cuffs after identifying risks of false heart-rate alarms and potential skin irritation from rough cuff edges, affecting more than 1,800 devices distributed across the US and multiple international markets. Because these issues touch core patient-monitoring functions that clinicians rely on, the recalls raise meaningful questions about product reliability, regulatory...

Masimo (MASI) has drawn fresh investor attention after voluntarily recalling specific Radius VSM disposable blood pressure cuffs and ECG pre connected sets, citing possible ECG alarm inaccuracies and skin irritation risks across a globally distributed inventory. See our latest analysis for Masimo. Set against the recent recall headlines, Masimo’s share price return of 41.25% year to date and 2.55% over 90 days suggests investors are still pricing in improving sentiment, even though the 5 year...